Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients

Muriel X G Draht, Kim M. Smits, Benjamin Tournier, Valerie Jooste, Caroline Chapusot, Beatriz Carvalho, Arjen H G Cleven, Sarah Derks, Kim A D Wouters, Eric J T Belt, Hein B A C Stockmann, Herman Bril, Matty P. Weijenberg, Piet A. van den Brandt, Adriaan P. de Bruïne, James G. Herman, Gerrit A. Meijer, Françoise Piard, Veerle Melotte, Manon Van Engeland

Research output: Contribution to journalArticle

Abstract

Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20-30% of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection (RET) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients.The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methylation was analyzed by using Cox regression analysis.In the first series, analyzed by MSP, CRC stage II patients (n=233) with RET methylated tumors had a significantly worse overall survival as compared to those with unmethylated tumors (HRmultivariable=2.51, 95%-CI: 1.42-4.43). Despite a significant prognostic effect of RET methylation in stage III patients of a second series, analyzed by MSP, the prognostic effect in stage II patients (n=231) was not statistically significant (HRmultivariable=1.16, 95%-CI 0.71-1.92). The third series (n=294), analyzed by pyrosequencing, confirmed a statistically significant association between RET methylation and poor overall survival in stage II patients (HRmultivariable=1.91, 95%-CI: 1.04-3.53). Our results show that RET promoter CpG island methylation, analyzed by two different techniques, is associated with a poor prognosis in stage II CRC in two independent series and a poor prognosis in stage III CRC in one series. RET methylation may serve as a useful and robust tool for clinical practice to identify high-risk stage II CRC patients with a poor prognosis. This merits further investigation.

Original languageEnglish (US)
Pages (from-to)679-688
Number of pages10
JournalMolecular Oncology
Volume8
Issue number3
DOIs
StatePublished - 2014

Fingerprint

CpG Islands
Methylation
Transfection
Colorectal Neoplasms
Neoplasms
Survival
Biomarkers
Regression Analysis

Keywords

  • Colon cancer
  • Colorectal cancer
  • DNA methylation
  • Methylation marker
  • Prognostic biomarker
  • REarranged during transfection (RET)

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Medicine
  • Medicine(all)

Cite this

Draht, M. X. G., Smits, K. M., Tournier, B., Jooste, V., Chapusot, C., Carvalho, B., ... Van Engeland, M. (2014). Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. Molecular Oncology, 8(3), 679-688. https://doi.org/10.1016/j.molonc.2014.01.011

Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. / Draht, Muriel X G; Smits, Kim M.; Tournier, Benjamin; Jooste, Valerie; Chapusot, Caroline; Carvalho, Beatriz; Cleven, Arjen H G; Derks, Sarah; Wouters, Kim A D; Belt, Eric J T; Stockmann, Hein B A C; Bril, Herman; Weijenberg, Matty P.; van den Brandt, Piet A.; de Bruïne, Adriaan P.; Herman, James G.; Meijer, Gerrit A.; Piard, Françoise; Melotte, Veerle; Van Engeland, Manon.

In: Molecular Oncology, Vol. 8, No. 3, 2014, p. 679-688.

Research output: Contribution to journalArticle

Draht, MXG, Smits, KM, Tournier, B, Jooste, V, Chapusot, C, Carvalho, B, Cleven, AHG, Derks, S, Wouters, KAD, Belt, EJT, Stockmann, HBAC, Bril, H, Weijenberg, MP, van den Brandt, PA, de Bruïne, AP, Herman, JG, Meijer, GA, Piard, F, Melotte, V & Van Engeland, M 2014, 'Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients', Molecular Oncology, vol. 8, no. 3, pp. 679-688. https://doi.org/10.1016/j.molonc.2014.01.011
Draht, Muriel X G ; Smits, Kim M. ; Tournier, Benjamin ; Jooste, Valerie ; Chapusot, Caroline ; Carvalho, Beatriz ; Cleven, Arjen H G ; Derks, Sarah ; Wouters, Kim A D ; Belt, Eric J T ; Stockmann, Hein B A C ; Bril, Herman ; Weijenberg, Matty P. ; van den Brandt, Piet A. ; de Bruïne, Adriaan P. ; Herman, James G. ; Meijer, Gerrit A. ; Piard, Françoise ; Melotte, Veerle ; Van Engeland, Manon. / Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients. In: Molecular Oncology. 2014 ; Vol. 8, No. 3. pp. 679-688.
@article{c7a5eb1a2ca849c48eb237f183d5d48e,
title = "Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients",
abstract = "Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20-30{\%} of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection (RET) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients.The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methylation was analyzed by using Cox regression analysis.In the first series, analyzed by MSP, CRC stage II patients (n=233) with RET methylated tumors had a significantly worse overall survival as compared to those with unmethylated tumors (HRmultivariable=2.51, 95{\%}-CI: 1.42-4.43). Despite a significant prognostic effect of RET methylation in stage III patients of a second series, analyzed by MSP, the prognostic effect in stage II patients (n=231) was not statistically significant (HRmultivariable=1.16, 95{\%}-CI 0.71-1.92). The third series (n=294), analyzed by pyrosequencing, confirmed a statistically significant association between RET methylation and poor overall survival in stage II patients (HRmultivariable=1.91, 95{\%}-CI: 1.04-3.53). Our results show that RET promoter CpG island methylation, analyzed by two different techniques, is associated with a poor prognosis in stage II CRC in two independent series and a poor prognosis in stage III CRC in one series. RET methylation may serve as a useful and robust tool for clinical practice to identify high-risk stage II CRC patients with a poor prognosis. This merits further investigation.",
keywords = "Colon cancer, Colorectal cancer, DNA methylation, Methylation marker, Prognostic biomarker, REarranged during transfection (RET)",
author = "Draht, {Muriel X G} and Smits, {Kim M.} and Benjamin Tournier and Valerie Jooste and Caroline Chapusot and Beatriz Carvalho and Cleven, {Arjen H G} and Sarah Derks and Wouters, {Kim A D} and Belt, {Eric J T} and Stockmann, {Hein B A C} and Herman Bril and Weijenberg, {Matty P.} and {van den Brandt}, {Piet A.} and {de Bru{\"i}ne}, {Adriaan P.} and Herman, {James G.} and Meijer, {Gerrit A.} and Fran{\cc}oise Piard and Veerle Melotte and {Van Engeland}, Manon",
year = "2014",
doi = "10.1016/j.molonc.2014.01.011",
language = "English (US)",
volume = "8",
pages = "679--688",
journal = "Molecular Oncology",
issn = "1574-7891",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients

AU - Draht, Muriel X G

AU - Smits, Kim M.

AU - Tournier, Benjamin

AU - Jooste, Valerie

AU - Chapusot, Caroline

AU - Carvalho, Beatriz

AU - Cleven, Arjen H G

AU - Derks, Sarah

AU - Wouters, Kim A D

AU - Belt, Eric J T

AU - Stockmann, Hein B A C

AU - Bril, Herman

AU - Weijenberg, Matty P.

AU - van den Brandt, Piet A.

AU - de Bruïne, Adriaan P.

AU - Herman, James G.

AU - Meijer, Gerrit A.

AU - Piard, Françoise

AU - Melotte, Veerle

AU - Van Engeland, Manon

PY - 2014

Y1 - 2014

N2 - Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20-30% of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection (RET) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients.The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methylation was analyzed by using Cox regression analysis.In the first series, analyzed by MSP, CRC stage II patients (n=233) with RET methylated tumors had a significantly worse overall survival as compared to those with unmethylated tumors (HRmultivariable=2.51, 95%-CI: 1.42-4.43). Despite a significant prognostic effect of RET methylation in stage III patients of a second series, analyzed by MSP, the prognostic effect in stage II patients (n=231) was not statistically significant (HRmultivariable=1.16, 95%-CI 0.71-1.92). The third series (n=294), analyzed by pyrosequencing, confirmed a statistically significant association between RET methylation and poor overall survival in stage II patients (HRmultivariable=1.91, 95%-CI: 1.04-3.53). Our results show that RET promoter CpG island methylation, analyzed by two different techniques, is associated with a poor prognosis in stage II CRC in two independent series and a poor prognosis in stage III CRC in one series. RET methylation may serve as a useful and robust tool for clinical practice to identify high-risk stage II CRC patients with a poor prognosis. This merits further investigation.

AB - Improved prognostic stratification of patients with TNM stage II colorectal cancer (CRC) is desired, since 20-30% of high-risk stage II patients may die within five years of diagnosis. This study was conducted to investigate REarranged during Transfection (RET) gene promoter CpG island methylation as a possible prognostic marker for TNM stage II CRC patients.The utility of RET promoter CpG island methylation in tumors of stage II CRC patients as a prognostic biomarker for CRC related death was studied in three independent series (including 233, 231, and 294 TNM stage II patients, respectively) by using MSP and pyrosequencing. The prognostic value of RET promoter CpG island methylation was analyzed by using Cox regression analysis.In the first series, analyzed by MSP, CRC stage II patients (n=233) with RET methylated tumors had a significantly worse overall survival as compared to those with unmethylated tumors (HRmultivariable=2.51, 95%-CI: 1.42-4.43). Despite a significant prognostic effect of RET methylation in stage III patients of a second series, analyzed by MSP, the prognostic effect in stage II patients (n=231) was not statistically significant (HRmultivariable=1.16, 95%-CI 0.71-1.92). The third series (n=294), analyzed by pyrosequencing, confirmed a statistically significant association between RET methylation and poor overall survival in stage II patients (HRmultivariable=1.91, 95%-CI: 1.04-3.53). Our results show that RET promoter CpG island methylation, analyzed by two different techniques, is associated with a poor prognosis in stage II CRC in two independent series and a poor prognosis in stage III CRC in one series. RET methylation may serve as a useful and robust tool for clinical practice to identify high-risk stage II CRC patients with a poor prognosis. This merits further investigation.

KW - Colon cancer

KW - Colorectal cancer

KW - DNA methylation

KW - Methylation marker

KW - Prognostic biomarker

KW - REarranged during transfection (RET)

UR - http://www.scopus.com/inward/record.url?scp=84899477967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899477967&partnerID=8YFLogxK

U2 - 10.1016/j.molonc.2014.01.011

DO - 10.1016/j.molonc.2014.01.011

M3 - Article

C2 - 24560444

AN - SCOPUS:84899477967

VL - 8

SP - 679

EP - 688

JO - Molecular Oncology

JF - Molecular Oncology

SN - 1574-7891

IS - 3

ER -